[2,3'-bipyridin]-5-amine | 35989-06-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: [2,3'-bipyridin]-5-amine
• 英文别名: 6-(Pyridin-3-yl)pyridin-3-amine；6-pyridin-3-ylpyridin-3-amine
• CAS: 35989-06-1
• 化学式: C₁₀H₉N₃
• 分子量: 171.202
• InChiKey: PAQALCKYBOJWEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  [2,3'-bipyridin]-5-amine 在 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 5-Methoxy-6-trifluoromethyl-2,3-dihydro-indole-1-carboxylic acid [2,3']bipyridinyl-5-ylamide
  参考文献：
  名称：

  Biarylcarbamoylindolines Are Novel and Selective 5-HT_2C Receptor Inverse Agonists:  Identification of 5-Methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a Potential Antidepressant/Anxiolytic Agent

  摘要：

  The evolution, synthesis, and biological activity of a novel series of 5-HT2C receptor inverse agonists are reported. Biarylcarbamoylindolines have been identified with excellent 5-HT2C affinity and selectivity over 5-HT2A receptors. In addition, (pyridyloxypyridyl)carbamoylindolines have been discovered with additional selectivity over the closely related 5-HT2B receptor. Compounds from this series are inverse agonists at the human cloned 5-HT2C receptor, completely abolishing basal activity in a functional assay. The new series have reduced P450 inhibitory liability compared to a previously described series of 1-(3-pyridylcarbamoyl)indolines (Bromidge et al. J. Med. Chem. 1998, 41, 1598) from which they evolved. Compounds from this series showed excellent oral activity in a rat mCPP hypolocomotion model and in animal models of anxiety. On the basis of their favorable biological profile, 32 (SB-228357) and 40 (SB-243213) have been selected for further evaluation to determine their therapeutic potential for the treatment of CNS disorders such as depression and anxiety.

  DOI：

  10.1021/jm990388c
• 作为产物：
  描述：

  2-溴-5-硝基吡啶 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 12.0h， 生成 [2,3'-bipyridin]-5-amine
  参考文献：
  名称：

  Biarylcarbamoylindolines Are Novel and Selective 5-HT_2C Receptor Inverse Agonists:  Identification of 5-Methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a Potential Antidepressant/Anxiolytic Agent

  摘要：

  The evolution, synthesis, and biological activity of a novel series of 5-HT2C receptor inverse agonists are reported. Biarylcarbamoylindolines have been identified with excellent 5-HT2C affinity and selectivity over 5-HT2A receptors. In addition, (pyridyloxypyridyl)carbamoylindolines have been discovered with additional selectivity over the closely related 5-HT2B receptor. Compounds from this series are inverse agonists at the human cloned 5-HT2C receptor, completely abolishing basal activity in a functional assay. The new series have reduced P450 inhibitory liability compared to a previously described series of 1-(3-pyridylcarbamoyl)indolines (Bromidge et al. J. Med. Chem. 1998, 41, 1598) from which they evolved. Compounds from this series showed excellent oral activity in a rat mCPP hypolocomotion model and in animal models of anxiety. On the basis of their favorable biological profile, 32 (SB-228357) and 40 (SB-243213) have been selected for further evaluation to determine their therapeutic potential for the treatment of CNS disorders such as depression and anxiety.

  DOI：

  10.1021/jm990388c

文献信息

• Design, synthesis, anticancer activity and docking studies of theophylline containing 1,2,3-triazoles with variant amide derivatives
  作者：Radhakrishnam Raju Ruddarraju、Adharvana Chari Murugulla、Ravindar Kotla、Muni Chandra Babu Tirumalasetty、Rajendra Wudayagiri、Shobha Donthabakthuni、Ravichandar Maroju

  DOI：10.1039/c6md00479b

  日期：——

  and 40 have pivotal anticancer activity. Among these, compounds 22 and 27 have significant cytotoxic activity in all three cell lines; the in silico docking studies also reveal that compounds 22, 27 and 36 have good dock scores, binding affinities and binding energies towards human epidermal growth factor receptor 2. This is the first report to demonstrate theophylline hybrids containing 1,2,3-triazoles

  设计并合成了一系列含有不同酰胺基团（ 22-41 ）的1,2,3-三唑的新茶碱类似物，其生物活性已被评估为潜在的抗癌药物。在四种癌细胞系中研究了合成化合物的抗癌活性。肺（A549）、结肠（HT-29）、乳腺（MCF-7）和黑色素瘤（A375）。此外，对这些化合物进行了计算 ADME 和 Lipinski 分析的筛选，然后针对细胞增殖中涉及的各种治疗靶点进行分子对接和结合能计算。体外结果表明化合物22、27、36和40具有关键的抗癌活性。其中，化合物22和27在所有三种细胞系中均具有显着的细胞毒活性；计算机对接研究还表明，化合物22、27和36对人表皮生长因子受体 2 具有良好的对接分数、结合亲和力和结合能。这是第一份证明含有 1,2,3-三唑的茶碱杂合体的报告潜在的抗癌剂。
• [EN] WNT PATHWAY MODULATORS<br/>[FR] MODULATEURS DE LA VOIE WNT
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2014175832A1

  公开（公告）日：2014-10-30

  The invention provides a compound of structure Ar1-Ar2-X-C(R1R2)-C(=O)-N(R3)-Ar3-Ar4 for modulating WNT activity. In this structure, Ar1, Ar2, Ar3 and Ar4 are, independently, optionally substituted aryl or heteroaryl groups; R1 and R3 are, independently, H or optionally substituted alkyl groups; R2 is H or an optionally substituted alkyl group or an alkylene group which, together with the carbon atom to which it is attached and X, forms a non-aromatic ring or an alkylene group which, together with the carbon atom to which it is attached and X and two adjacent atoms of Ar2, forms a non-aromatic ring; X is O, CR4R5, N or NR4, wherein if X is N, it is bonded to R2; R4 is H, optionally substituted alkyl or an alkylene chain, optionally containing a heteroatom and/or a carbonyl group, which, together with the C or N to which it is attached and two adjacent atoms of Ar2, forms a non-aromatic ring; R5 is H, NH2 or an optionally substituted alkyl group.

  该发明提供了一种结构为Ar1-Ar2-X-C(R1R2)-C(=O)-N(R3)-Ar3-Ar4的化合物，用于调节WNT活性。在这种结构中，Ar1、Ar2、Ar3和Ar4分别是可选择取代的芳基或杂环芳基；R1和R3分别是H或可选择取代的烷基；R2是H或可选择取代的烷基或与其连接的碳原子和X形成非芳香环的烷基，或者与其连接的碳原子、X和Ar2的两个相邻原子形成非芳香环的烷基；X是O、CR4R5、N或NR4，如果X是N，则与R2相结合；R4是H、可选择取代的烷基或含有杂原子和/或羰基的烷基链，与其连接的C或N以及Ar2的两个相邻原子形成非芳香环；R5是H、NH2或可选择取代的烷基。
• [EN] PHTHALIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY<br/>[FR] DÉRIVÉS DE PHTALIMIDE À TITRE DE MODULATEURS DE LA VOIE WNT
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2015187094A1

  公开（公告）日：2015-12-10

  The present invention relates to compounds of formula (I), [Formula should be inserted here] pharmaceutically acceptable salts, solvates and polymorphs thereof, including all tautomers and stereoisomers thereof, wherein R1 is alkyl; alkoxy-alkyl-; carbocyclyl; heterocyclyl; aryl; heteroaryl; aryl-alkyl-; heteroaryl- alkyl-; carbocyclyl-alkyl-; or heterocyclyl-alkyl-; R2 is H or alkyl; R3 is H or alkyl; Y is aryl; heteroaryl; carbocyclyl; or heterocyclyl; and Z is aryl; heteroaryl; carbocyclyl; or heterocyclyl.

  本发明涉及化合物的公式（I），其药学上可接受的盐、溶剂和多型体，包括其所有互变异构体和立体异构体，其中R1是烷基；烷氧基烷基；碳环烷基；杂环烷基；芳基；杂芳基；芳基烷基；杂芳基烷基；碳环烷基烷基；或杂环烷基烷基；R2是H或烷基；R3是H或烷基；Y是芳基；杂芳基；碳环烷基；或杂环烷基；Z是芳基；杂芳基；碳环烷基；或杂环烷基。
• NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS
  申请人：MEDIBIOFARMA, S.L.

  公开号：EP3498694A1

  公开（公告）日：2019-06-19

  The present invention relates to novel benzamides derivatives of formula (I) as modulators of PPAR-gamma receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use in the treatment of pathological conditions, disorders or diseases that can improve by modulation of PPAR-gamma receptor, such as cancer; metabolic diseases, inflammatory diseases, respiratory disorders, autoimmune diseases, neurodegenerative diseases, cardiovascular diseases and renal diseases.

  本发明涉及一种新型苯甲酰胺衍生物的公式(I)，作为PPAR-gamma受体调节剂，以及其制备方法、包含所述化合物的药物组合物，以及用于治疗可以通过调节PPAR-gamma受体而改善的病理条件、疾病或疾病的该化合物，例如癌症；代谢性疾病、炎症性疾病、呼吸系统疾病、自身免疫疾病、神经退行性疾病、心血管疾病和肾脏疾病。
• [EN] NOVEL KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060113A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种具有公式（I）的新化合物，能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物在治疗多种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。